Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Markus W LöfflerStefania GoriFrancesco IzzoAndrea Mayer-MoklerPaolo Antonio AsciertoAlfred KönigsrainerYuk Ting MaBruno SangroSven FrancqueLuisa VonghiaAlessandro InnoAntonio AvalloneJörg LudwigDiego Duarte AlcobaChristian FlohrKatrin AslanRegina MendrzykHeiko SchusterMarco BorrelliDanila ValmoriTanguy ChaumetteRegina HeidenreichCécile GouttefangeasGreta ForlaniMaria TagliamonteCaterina FuscoRoberta PentaMercedes IñarrairaeguiUlrike Gnad-VogtCarsten ReinhardtToni WeinschenkRoberto Sergio AccollaHarpreet Singh-JasujaHans-Georg RammenseeLuigi BuonaguroPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Immunotherapy may provide a great improvement in treatment options for HCC. HepaVac-101 is a first-in-human clinical vaccine trial with multiple novel HLA class I- and class II-restricted TAAs against HCC. The results are initial evidence for the safety and immunogenicity of the vaccine. Further clinical evaluations are warranted.